Pomerantz Law Firm Launches Investigation into ImmunityBio, Inc. for Potential Securities Fraud
In a significant move triggering investor concern, Pomerantz LLP, a law firm renowned for handling class action lawsuits, has commenced an investigation on behalf of investors of ImmunityBio, Inc., trading on NASDAQ under the ticker IBRX. This inquiry focuses on potential securities fraud or other unlawful business practices allegedly engaged in by ImmunityBio's management, including officers and directors.
The impetus for this investigation follows a press release issued by ImmunityBio on January 23, 2026, detailing updated results from their Phase 2 clinical trial, known as QUILT 3.078. This particular study evaluated a new chemotherapy-free immunotherapy regimen aimed at treating patients with recurrent or progressive glioblastoma, a particularly aggressive form of brain cancer. Despite the hope surrounding this innovative approach, the trial's disclosure that 'median overall survival'—a critical benchmark for the trial—'has not yet been reached' raised flags among investors.
On the same day ImmunityBio issued its press release, the company’s stock saw a notable decline, falling $0.89 or 12.13%, which brought the closing price down to $6.45 per share. This significant drop has prompted questions from shareholders about the veracity of the information provided by ImmunityBio leading up to this disclosure.
Pomerantz LLP is inviting affected investors to take action and has provided contact details for anyone seeking to join the class action. Interested parties can reach out to Danielle Peyton via email or phone to discuss the implications of this investigation and explore their legal options.
With offices established across major cities such as New York, Chicago, and Los Angeles, Pomerantz is widely recognized as one of the leading firms specializing in class actions related to corporate, securities, and antitrust matters. The firm boasts a rich history of successfully advocating for victims of securities fraud and misconduct, recovering substantial damages for class members. Founded by Abraham L. Pomerantz, a pioneer in the realm of class action litigation, the firm continues the legacy of fighting for justice for its clients. More information can be found on their website at www.pomlaw.com.
In summary, the upcoming investigation led by Pomerantz LLP into ImmunityBio may have significant ramifications for the company and its investors. As the legal landscape evolves, it’s crucial for impacted shareholders to stay informed and consider their options diligently. The outcome of this probe could potentially alter the trajectory of ImmunityBio’s operations and investor confidence moving forward.
The impetus for this investigation follows a press release issued by ImmunityBio on January 23, 2026, detailing updated results from their Phase 2 clinical trial, known as QUILT 3.078. This particular study evaluated a new chemotherapy-free immunotherapy regimen aimed at treating patients with recurrent or progressive glioblastoma, a particularly aggressive form of brain cancer. Despite the hope surrounding this innovative approach, the trial's disclosure that 'median overall survival'—a critical benchmark for the trial—'has not yet been reached' raised flags among investors.
On the same day ImmunityBio issued its press release, the company’s stock saw a notable decline, falling $0.89 or 12.13%, which brought the closing price down to $6.45 per share. This significant drop has prompted questions from shareholders about the veracity of the information provided by ImmunityBio leading up to this disclosure.
Pomerantz LLP is inviting affected investors to take action and has provided contact details for anyone seeking to join the class action. Interested parties can reach out to Danielle Peyton via email or phone to discuss the implications of this investigation and explore their legal options.
With offices established across major cities such as New York, Chicago, and Los Angeles, Pomerantz is widely recognized as one of the leading firms specializing in class actions related to corporate, securities, and antitrust matters. The firm boasts a rich history of successfully advocating for victims of securities fraud and misconduct, recovering substantial damages for class members. Founded by Abraham L. Pomerantz, a pioneer in the realm of class action litigation, the firm continues the legacy of fighting for justice for its clients. More information can be found on their website at www.pomlaw.com.
In summary, the upcoming investigation led by Pomerantz LLP into ImmunityBio may have significant ramifications for the company and its investors. As the legal landscape evolves, it’s crucial for impacted shareholders to stay informed and consider their options diligently. The outcome of this probe could potentially alter the trajectory of ImmunityBio’s operations and investor confidence moving forward.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.